Sci PharmtechTPE:4119 -0.34%67 EBITDA Margin % is 30.56% as of Dec. 2025, which is 11% below its 10-year median of 34.27. GuruFocus rates TPE:4119 with a GF Score™ of 67/100 and a GF Value™ of NT$96.43 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, Sci Pharmtech ranks better than 80.73% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sci Pharmtech's EBITDA for the
three
months ended in Dec. 2025 was NT$109 Mil. Sci Pharmtech's Revenue for the
three
months ended in Dec. 2025 was NT$355 Mil. Therefore, Sci Pharmtech's EBITDA margin for the quarter that ended in Dec. 2025 was 30.56%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sci Pharmtech EBITDA Margin % Related Terms
Sci Pharmtech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech (TPE:4119) has a EBITDA Margin % of 30.56% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sci Pharmtech and its competitors. This is 11% below median its historical median of 34.27. Over the past decade, Sci Pharmtech's EBITDA Margin % has ranged from 14.96 to 58.16. According to the industry distribution chart, Sci Pharmtech ranks #184 out of 955 companies in the Drug Manufacturers industry, placing it in the top 19.3%.
Is Sci Pharmtech's EBITDA Margin % too high?
Sci Pharmtech's current EBITDA Margin % of 30.56% is 11% below median its 10-year median of 34.27. Over the past 10 years, this metric has ranged from a low of 14.96 to a high of 58.16. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Sci Pharmtech's value of 30.56% is 145.7% above this industry median. Based on the distribution chart, Sci Pharmtech ranks #184 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sci Pharmtech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #184 out of 955 companies for EBITDA Margin %. This places Sci Pharmtech in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Sci Pharmtech's value of 30.56% is 145.7% above this benchmark. Historically, Sci Pharmtech's own EBITDA Margin % has ranged from 14.96 to 58.16 over the past decade. While the company's 10-year median is 34.27 vs. the industry median of 12.44, Sci Pharmtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current EBITDA Margin % of 30.56% is 145.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current EBITDA Margin % is 30.56%, which is 11% below median its own 10-year median of 34.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$96.43, compared to a current price of NT$44.50 — trading 53.9% below its estimated fair value. The current EBITDA Margin % is 30.56%, which is 11% below median its 10-year median of 34.27 and 145.7% above the Drug Manufacturers industry median of 12.44. Sci Pharmtech's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current EBITDA Margin % is 30.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$44.50 is trading 53.9% below its estimated GF Value™ of NT$96.43.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
EBITDA Margin %: 30.56% (11% below median its 10-year median of 34.27)
GF Value™: NT$96.43 vs. price of NT$44.50 (53.9% below fair value)
Industry Position: 145.7% above the Drug Manufacturers median (#184 of 955)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
67GF Score
Get the complete analysis for TPE:4119
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
